

617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches

688 [Variation in Stem Cell Driven Hierarchies Underlies Clinical Outcome and Drug Response in AML](#)

Andy G.X. Zeng, Amanda Mitchell, Oleksandr Galkin, et al.

689 [Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia](#)

Benjamin J. Huang, Jenny L. Smith, Rhonda E. Ries, et al.

690 [Single-Cell Characterization of Acute Myeloid Leukemia \(AML\) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy](#)

Hussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.

691 [*Setbp1* Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human *FLT3-ITD*-Mutant AMLs](#)

Suruchi Pacharne, Oliver M. Dovey, Jonathan L Cooper, et al.

692 [CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia \(AML\) in Remission after Intensive Chemotherapy \(IC\) Independent of the Presence of Measurable Residual Disease \(MRD\) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial](#)

Gail J. Roboz, Farhad Ravandi, Andrew H Wei, et al.

693 [Outcomes of *TP53*-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine](#)

Kunhwa Kim, Abhishek Maiti, Tapan M. Kadia, et al.